Literature DB >> 31673695

Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Alison M Boyce1, Michael T Collins1.   

Abstract

Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare disorder of striking complexity. It arises from somatic, gain-of-function mutations in GNAS, leading to mosaic Gα s activation and inappropriate production of intracellular cyclic adenosine monophosphate (cAMP). The clinical phenotype is largely determined by the location and extent of affected tissues, and the pathophysiological effects of Gα s activation within these tissues. In bone, Gα s activation results in impaired differentiation of skeletal stem cells, leading to discrete skeletal lesions prone to fracture, deformity, and pain. Extraskeletal manifestations include a variable combination of hyperpigmented macules and hyperfunctioning endocrinopathies. Distinctive age-related changes in disease development has key effects on histologic, radiographic, and clinical features. FD/MAS thus presents along a uniquely broad clinical spectrum, and the resulting challenges in diagnosis and management can be difficult for clinicians. This review presents FD/MAS in the context of a mosaic disorder of Gα s activation, providing an intellectual framework within which to understand, evaluate, and treat this interesting disease. It includes a comprehensive summary of current understanding of FD/MAS pathogenesis, and a detailed discussion of clinical presentation and management. Critical areas of unmet need are highlighted, including discussion of key challenges and potential solutions to advance research and clinical care in FD/MAS. Published by Oxford University Press on behalf of the Endocrine Society 2019.

Entities:  

Keywords:  fibroblast growth factor 23; growth hormone excess; metabolic bone disease; precocious puberty; skeletal stem cells; somatic mosaicism

Mesh:

Substances:

Year:  2020        PMID: 31673695      PMCID: PMC7127130          DOI: 10.1210/endrev/bnz011

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  173 in total

1.  The role of type 1 and type 2 5'-deiodinase in the pathophysiology of the 3,5,3'-triiodothyronine toxicosis of McCune-Albright syndrome.

Authors:  Francesco S Celi; Giuseppe Coppotelli; Aaron Chidakel; Marilyn Kelly; Beth A Brillante; Thomas Shawker; Natasha Cherman; Penelope P Feuillan; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

2.  Hepatic Lesions Associated With McCune Albright Syndrome.

Authors:  Lauren Johansen; Wolfram Haller; Manigandan Thyagarajan; Deirdre Kelly; Patrick McKiernan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-04       Impact factor: 2.839

3.  Glucocorticoids decrease interleukin-6 levels and induce mineralization of cultured osteogenic cells from children with fibrous dysplasia.

Authors:  R P Stanton; G M Hobson; B E Montgomery; P A Moses; S M Smith-Kirwin; V L Funanage
Journal:  J Bone Miner Res       Date:  1999-07       Impact factor: 6.741

4.  Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome.

Authors:  M E Escobar; M Gryngarten; H Domené; G Ropelato; M R López; C Bergadá
Journal:  J Pediatr Adolesc Gynecol       Date:  1997-08       Impact factor: 1.814

5.  Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.

Authors:  Horacio Plotkin; Frank Rauch; Leonid Zeitlin; Craig Munns; Rose Travers; Francis H Glorieux
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

6.  Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw.

Authors:  Tarek Metwally; Andrea Burke; Jeffrey Y Tsai; Michael T Collins; Alison M Boyce
Journal:  J Oral Maxillofac Surg       Date:  2016-04-07       Impact factor: 1.895

7.  Postpubertal Persistent Hyperestrogenemia in McCune-Albright Syndrome: Unilateral Oophorectomy Improved Fertility but Detected an Unexpected Borderline Epithelial Ovarian Tumor.

Authors:  Nicolas Chevalier; Françoise Paris; Sylvie Fontana; Jérôme Delotte; Laura Gaspari; Patricia Ferrari; Charles Sultan; Patrick Fénichel
Journal:  J Pediatr Adolesc Gynecol       Date:  2015-04-07       Impact factor: 1.814

Review 8.  Intramuscular myxoma: a clinicopathologic study of 51 cases with emphasis on hypercellular and hypervascular variants.

Authors:  G P Nielsen; J X O'Connell; A E Rosenberg
Journal:  Am J Surg Pathol       Date:  1998-10       Impact factor: 6.394

9.  Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features.

Authors:  Yuko Omori; Yusuke Ono; Mishie Tanino; Hidenori Karasaki; Hiroshi Yamaguchi; Toru Furukawa; Katsuro Enomoto; Jun Ueda; Atsuko Sumi; Jin Katayama; Miho Muraki; Kenzui Taniue; Kuniyuki Takahashi; Yoshiyasu Ambo; Toshiya Shinohara; Hiroshi Nishihara; Junpei Sasajima; Hiroyuki Maguchi; Yusuke Mizukami; Toshikatsu Okumura; Shinya Tanaka
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 22.682

10.  Gs G protein-coupled receptor signaling in osteoblasts elicits age-dependent effects on bone formation.

Authors:  Edward C Hsiao; Benjamin M Boudignon; Bernard P Halloran; Robert A Nissenson; Bruce R Conklin
Journal:  J Bone Miner Res       Date:  2010-03       Impact factor: 6.741

View more
  16 in total

1.  A case report of McCune-Albright syndrome with hepatic manifestations.

Authors:  Mohammad Haddadi; Elahe Lal Kheirkhah; Mojgan Ansari; Samieh Ahmadzade; Zeinab Taraz; Saeid Yazdi
Journal:  Clin Case Rep       Date:  2022-07-19

2.  Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors.

Authors:  Raya E S Geels; Maartje E Meier; Amanda Saikali; Roula Tsonaka; Natasha M Appelman-Dijkstra; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2021-11-17       Impact factor: 6.390

3.  Genotype-Phenotype Correlation in Fibrous Dysplasia/McCune-Albright Syndrome.

Authors:  Maria Zhadina; Kelly L Roszko; Raya E S Geels; Luis F de Castro; Michael T Collins; Alison M Boyce
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

4.  Burosumab treatment for fibrous dysplasia.

Authors:  Anne Gladding; Vivian Szymczuk; Bethany A Auble; Alison M Boyce
Journal:  Bone       Date:  2021-05-11       Impact factor: 4.626

5.  Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases.

Authors:  Maartje E Meier; Wouter van der Bruggen; Michiel A J van de Sande; Natasha M Appelman-Dijkstra
Journal:  Bone Rep       Date:  2021-04-09

Review 6.  Pathogenic postzygotic mosaicism in the tyrosine receptor kinase pathway: potential unidentified human disease hidden away in a few cells.

Authors:  Irene Tiemann-Boege; Theresa Mair; Atena Yasari; Michal Zurovec
Journal:  FEBS J       Date:  2020-09-05       Impact factor: 5.542

Review 7.  Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia-Risks and Benefits.

Authors:  Kristen S Pan; Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2021-02-22       Impact factor: 5.163

8.  Zoledronic Acid in a Mouse Model of Human Fibrous Dysplasia: Ineffectiveness on Tissue Pathology, Formation of "Giant Osteoclasts" and Pathogenetic Implications.

Authors:  Alessandro Corsi; Biagio Palmisano; Emanuela Spica; Annamaria Di Filippo; Ilenia Coletta; Michele Dello Spedale Venti; Rossella Labella; Francesca Fabretti; Samantha Donsante; Cristina Remoli; Marta Serafini; Mara Riminucci
Journal:  Calcif Tissue Int       Date:  2020-09-01       Impact factor: 4.333

9.  Squamous Cell Carcinoma of the Lung in McCune-Albright Syndrome.

Authors:  Vinai Y Reddy; Erika Tvedten; Muthanna Louis
Journal:  Cureus       Date:  2021-03-28

10.  A CREB1-miR-181a-5p loop regulates the pathophysiologic features of bone marrow stromal cells in fibrous dysplasia of bone.

Authors:  Yu Fu; Zhili Xin; Ziji Ling; Hanyu Xie; Tao Xiao; Xin Shen; Jialin Lin; Ling Xu; Hongbing Jiang
Journal:  Mol Med       Date:  2021-07-22       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.